Evogene Schedules First Quarter 2024 Financial Results Release
Zoom conference call scheduled for 9:00 AM ET REHOVOT, Israel, May 9, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize
Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
Preliminary data from Biomica's Phase 1 study of BMC128 will be showcased at the conference REHOVOT, Israel, April 16, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company de
Analysts Offer Insights on Healthcare Companies: Evogene (EVGN), Edwards Lifesciences (EW) and Nurix Therapeutics (NRIX)
Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd....
Evogene's New Venture Targets Sustainable Protein Market
Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry
Finally Foods is financed by the Israeli Innovation Authority (IIA) and The Kitchen Hub, and will be granted a license to utilize Evogene's AI technology REHOVOT, Israel, April 2, 2024 /PRNewswire/ -
Evogene (EVGN) Receives a Buy From Lake Street
Evogene Ltd. Announces $7.3 Million Share Sale Plan
Evogene Announces Filing of Annual Report on Form 20-F
REHOVOT, Israel, March 28, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and d
Evogene Gets Non-compliance Notice From Nasdaq
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing
Earnings Call Summary | Evogene(EVGN.US) Q4 2023 Earnings Conference
The following is a summary of the Evogene Ltd. (EVGN) Q4 2023 Earnings Call Transcript:Financial Performance:Evogene reported a significant increase in revenue, moving from approximately $1.7 million
Israeli Company Reports Record 2023 Revenue, Wants To Transition Cannabis Operations To 'Third Party'
Evogene Ltd. (NASDAQ:EVGN) (TASE: EVGN) announced on Thursday its financial results for the fourth quarter and full-year period ending December 31, 2023.In the fourth quarter revenues amounted to $578
Evogene GAAP EPS of -$0.13 Beats by $0.01, Revenue of $0.58M Misses by $0.31M
Evogene 4Q Rev $578,000 >EVGN
Evogene 4Q Rev $578,000 >EVGN
Press Release: Evogene Reports Fourth Quarter and Full Year 2023 Financial Results
Evogene Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire REHOVOT, Israel, March 7, 2024 Conference call and webcast: today, March 7, 2024, 9:00 am E.T. +1-888-407-2553 or +9
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. • Stevanato Gr (NYSE:STVN) is likely to report quarte
Evogene Unit, Corteva Agriscience Identify New Potential Class of Herbicidal Molecules
Evogene's (EVGN) AgPlenus unit said Wednesday that it achieved a milestone in its herbicide development collaboration with Corteva (CTVA) Agriscience after it identified a new family of molecules that
Evogene Q4 2023 Earnings Preview
No Data